Pfizer: Champix GP referral tear-off pad seen by patients promoted a POM and undermined GP prescribing (AUTH/2023/7/07)

📊

Key facts

⌄

Case	AUTH/2023/7/07
Complainant	Teaching PCT pharmacist
Respondent	Pfizer Limited
Product	Champix (varenicline)
Material	GP referral aid (pad of tear-off letters), ref SCE021
Main issue	Exaggerated “therapy of choice” claim; promotional POM material provided to patients; undermined GP independent prescribing and GP/patient relationship
Breach clauses	Clause 2; Clause 7.10; Clause 9.1
Sanctions	Undertaking received; recovery of items required by Appeal Board (Paragraph 11.3)
Complaint received	18 July 2007
Case completed	18 October 2007
Applicable Code year	2006
Source	PMCPA case page and Code of Practice Review November 2007

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A teaching PCT pharmacist complained about a Pfizer Champix (varenicline) GP referral aid (a pad of tear-off letters) used by smoking cessation service providers (including community pharmacists and other health professionals).
The letter was completed during/after a consultation and handed to the patient to give to their GP.
The letter stated: “Following consultation, we recommend that… the therapy of choice is varenicline tartrate (Champix)” and included dosage details.
It included a checklist (“To ensure that Champix is suitable for this patient, we have already checked…”) covering contraindications and warnings/precautions, including psychiatric history, plus a highlighted box: “In cases where the patient has epilepsy or a history of psychiatric illness, the clinical justification for recommending Champix is described below…”.
The letter encouraged enrolment in Pfizer’s LifeREWARDS programme (noted as only open to those already prescribed Champix).
It included: “Prescribing information for Champix can be found at the back of this document. For more information, please contact your local Pfizer representative”.
Pfizer argued the item had been pre-vetted by the MHRA, was intended as HCP-to-HCP communication, and expected it to be sent so patients would not see it (eg sealed envelope), though the Appeal Board considered it inevitable some patients would see it.

⚖️

⌄

Breach found (Panel), upheld on appeal (Appeal Board).
The claim “therapy of choice” was ruled exaggerated and unsubstantiated.
The referral letter was ruled promotional and unacceptable to provide to patients for a prescription-only medicine; it was found to undermine the GP’s independent prescribing decision and the GP/patient relationship.
The matter was reported by the Panel to the Appeal Board for consideration of further sanctions (Paragraph 8.2).
Appeal Board required Pfizer to recover the GP referral aids (Paragraph 11.3), despite noting they were no longer distributed.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access